SARS-CoV-2 neutralizing monoclonal antibodies (mAbs)
- Posted By
10Pointer
- Categories
Health Issues
- Published
24th Oct, 2020
-
- Serum Institute of India (SII) andthe International AIDS Vaccine Initiative (IAVI) have announced an agreement with pharmaceutical major Merck to develop SARS-CoV-2 neutralizing monoclonal antibodies (mAbs).
- Monoclonal antibodies (mAbs) are man-made proteinsthat act like human antibodies in the immune system.
- These antibodies are co-invented by IAVI and Scripps Research as ‘innovative interventions’ to address the COVID-19 pandemic.
